About an2 therapeutics inc - ANTX
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley in 2017 and is headquartered in Menlo Park, CA.
ANTX At a Glance
AN2 Therapeutics, Inc.
1300 El Camino Real
Menlo Park, California 94025
| Phone | 1-650-331-9090 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -35,174,000.00 | |
| Sector | Health Technology | Employees | 21 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ANTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.589 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.618 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
ANTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,674,952.381 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ANTX Liquidity
| Current Ratio | 6.874 |
| Quick Ratio | 6.874 |
| Cash Ratio | 6.651 |
ANTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -45.67 |
| Return on Equity | -52.145 |
| Return on Total Capital | -66.291 |
| Return on Invested Capital | -52.145 |
ANTX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |